Abstract: The present invention relates, by way of novel industrial products, to osides selected from the group consisting of:(i) the .beta.-.eta.-phenylthioxylosides of the formula: ##STR1## in which: R represents a hydrogen atom, a halogen atom, a nitro group or a cyano group,A represents the sulfur atom or the oxygen atom,B represents a CH.sub.2, CHOH or CO group andY represents the hydrogen atom or an acyl group; and(ii) epimers thereof when B is CHOH.These products are useful in therapy as antithrombotics.

Abstract: The present invention relates to .beta.-D-phenylthioxyloside compounds selected from the group consisting of:(i) the .beta.-D-phenylthioxylosides of the formula: ##STR1## in which: R.sub.1 and R.sub.2, which can be identical or different, which represent a hydrogen atom or a trifluoromethy or cyano group,A represents CHOH or CO andY represents a hydrogen atom or an acyl group; and(ii) epimers thereof when A is CHOH.The said .beta.-D-phenylthioxyloside compounds are useful in therapy as antithrombotics.

Abstract: The present invention relates to a novel dosage form of fenofibrate containing fenofibrate and a solid surfactant which have been co-micronized.It also relates to the method for the preparation of this dosage form and its use for improving the bioavailabity in vivo.

Abstract: The present invention relates, by way of novel industrial products, to osides selected from the group consisting of:(i) the .beta.-D-phenylthioxylosides of the formula: ##STR1## in which: R represents a hydrogen atom, a halogen atom, a nitro group or a cyano group,A represents the sulfur atom or the oxygen atom,B represents a CH.sub.2, CHOH or CO group andY represents the hydrogen atom or an acyl group; and(ii) epimers thereof when B is CHOH.These products are useful in therapy as antithrombotics.

Abstract: The present invention relates to a dosage calendar comprising at least two time scales (2, 3), the units 21a, 21b . . . ) of the first scale (2) being the day in the month or week or else a fraction of a day in the month, week or day, and the second scale (3) having a number of unit elements (31a, 31b . . . ) with a value of seven or a multiple of seven, which is equal to or directly greater than the total number of unit doses of drug to be administered, according to whether or not this number is divisible by seven, at least one of the two said scales including a recognition mark which can be changed by the user during the treatment.

Abstract: The present invention relates to novel asymmetrical esters derived from 1,4-dihydrophyridine-3,5-dicarboxylic acid, of the formula: ##STR1## in which: R.sub.1 represents a C.sub.1 -C.sub.4 alkyl group, R.sub.2 represents a C.sub.1 -C.sub.4 alkyl group, a benzyl group, a benzoyl group or a phenyl group optionally substituted by one or more C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkyl, cyano, nitro, hydroxyl or trifluoromethyl groups or by one or more halogen atoms, and R.sub.3 and R.sub.4, which are identical or different, each represent the hydrogen atom, a nitro group or a chlorine atom, their optical isomers and diastereoisomers and also the corresponding addition salts.These novel esters are useful in therapy, especially as antihypertensives.

Abstract: The present invention relates to a method for the preparation of fibrates of the formula I according to the mechanism: ##STR1## in which R.sub.1 represents especially a halogen atom (in particular F, Cl or Br, the preferred halogen atom being Cl) or an acetyl, (4-chlorophenyl)hydroxymethyl, 4-chlorobenzoyl or 2-(4-chlorobenzamido)ethyl group and R.sub.2 represents a C.sub.1 -C.sub.4 alkyl group in which the hydrocarbon chain is linear or branched, the reaction V+VI being carried out without a solvent.